Ruxolitinib plus steroids for acute graft versus host disease: a multicenter, randomized, phase 3 trial.
Dou L, Zhao Y, Yang J, Deng L, Wang N, Zhang X, Liu Q, Yang Y, Wei Z, Wang F, Jiao Y, Li F, Luan S, Hu L, Gao S, Liu C, Liu X, Yan J, Zhang X, Zhou F, Lu P, Liu D.
Dou L, et al. Among authors: luan s.
Signal Transduct Target Ther. 2024 Oct 23;9(1):288. doi: 10.1038/s41392-024-01987-x.
Signal Transduct Target Ther. 2024.
PMID: 39438467
Free PMC article.
Clinical Trial.